Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccines against nipah virus, and methods of using same

A technology of Nipah virus and antigen, applied in antiviral agents, viruses, vaccines, etc., can solve serious problems

Pending Publication Date: 2021-06-01
THE WISTAR INST OF ANATOMY & BIOLOGY
View PDF72 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients infected with NiV usually develop severe pulmonary disease and encephalitis after an incubation period of 5-14 days, however, NiV infection may remain latent and reactivate later

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccines against nipah virus, and methods of using same
  • Vaccines against nipah virus, and methods of using same
  • Vaccines against nipah virus, and methods of using same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0208] Example 1: Construction and Characterization of the Immune Response to a Novel Synthetic DNA Vaccine Against Nipah Virus

[0209] DNA vaccines have been developed to elicit immune responses against shared viral proteins in various emerging infectious diseases. The present invention demonstrates the development and use of the Nipah vaccine to induce an immune response in vaccinated subjects.

[0210] The materials and methods used are now described

[0211] Plasmid vaccine construction

[0212] Plasmids were developed to express consensus NiV fusion (F) or NiV glycoprotein (G) antigens (Figure 1 and Figure 2).

[0213] Animals and Vaccinations

[0214] Balb / C mice were immunized with NiV-F, NiV-G or pVaxl and electroporated (EP) twice every 2 weeks. One week after the second immunization, serum and splenocytes were isolated from individual mice (n=4).

[0215] Now describe the results of the experiment

[0216] NiV in mice Immunogenicity of DNA Vaccines ...

Embodiment 2

[0218] Example 2: Sequence

[0219] SEQ ID NO: 1 - Nucleotide sequence of the consensus NiV fusion (F) immunogen

[0220]

[0221] SEQ ID NO:2 - Amino acid sequence of the consensus NiV-fusion (F) immunogen

[0222]

[0223] SEQ ID NO:3 - Nucleotide sequence of a consensus NiV-fusion immunogen operably linked to a sequence encoding an IgE leader sequence and two stop codons

[0224]

[0225]

[0226] SEQ ID NO:4 - Amino acid sequence of the consensus NiV-fusion immunogen operably linked to the IgE leader

[0227]

[0228] SEQ ID NO:5 - Nucleotide sequence of the consensus NiV-glycoprotein (G) immunogen

[0229]

[0230]

[0231] SEQ ID NO:6 - Amino acid sequence of the consensus NiV-G immunogen

[0232]

[0233] SEQ ID NO:7 - Nucleotide sequence of the consensus NiV-G immunogen operably linked to a sequence encoding an IgE leader sequence and two stop codons

[0234]

[0235] SEP ID NO: 8 - Amino acid sequence of the consensus NiV-G immunog...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one Nipah virus (NiV) antigen that elicits an immune response in a mammal against NiV virus, and methods of use thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 62 / 720,393, filed August 21, 2018, the entire contents of which are incorporated herein in their entirety. technical field [0003] The present invention relates to the recombinant nucleotide sequence encoding Nipah virus antigen and its functional fragments. The present invention also relates to combinations of multiple recombinant nucleotide sequences encoding Nipah virus antigens for use in generating immunity against Nipah virus disease. The compositions of the invention provide improved methods for inducing an immune response and for prophylactically and / or therapeutically immunizing individuals against Nipah virus. Background technique [0004] Nipah virus (NiV) is a member of the Paramyxoviridae family and was first reported in 1998. In this case, pigs are the intermediate host. However, in subsequent NiV outbreaks, there was no intermediate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/12A61K39/155A61P31/12C07K14/115C12N7/00
CPCA61P31/12A61K39/12C12N2760/18234A61K2039/53C07K14/005C12N2760/18222A61P37/04A61P31/14A61K39/155C12N7/00C12N2760/18271
Inventor 卡尔·穆图马尼大卫·韦纳
Owner THE WISTAR INST OF ANATOMY & BIOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com